Search
Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial
Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.
Read moreMore than science: the European Affairs program at EHA2023
To develop and administer safe, innovative and effective treatments for patients with blood diseases, hematologists need an effective and enabling regulatory environment.
Read moreSWG Educational Activities
EHA-SWG meetingsAn EMSCO meeting was held in October 2023 (Nice, France).
Read morePosition of EHA on Access to Medicines
There are many factors that compromise patient access to medicine. First and foremost, for a drug to be available, one has to be developed.
European Affairs
Advocating & collaborating for hematologyEHA serves as the face and voice of hematology and hematology professionals in Europe.
Read moreEHA at ICH meeting: Excessive bureaucracy harms patient safety and innovation
To solicit input from a wide range of non-ICH members about the revision of ICH E8(R1), ICH held a Public Meeting on ICH E8(R1) “General Considerations for Clinical Studies” (Silver Spring, USA, October 31, 2019).
Read moreEHA Research Grants
The call for applications is closed. EHA Research Grants support talented junior researchers in advancing their career—for example, by helping them move towards becoming the leader of a research group.
Read more